Does Enzalutamide Really Reduce the Risk of Progression Compared With Bicalutamide in Patients With Castration-Resistant Prostate Cancer?
- PMID: 28034074
- DOI: 10.1200/JCO.2016.68.0389
Does Enzalutamide Really Reduce the Risk of Progression Compared With Bicalutamide in Patients With Castration-Resistant Prostate Cancer?
Comment in
-
Reply to M.A.N. Şendur et al and J. Michels.J Clin Oncol. 2017 Jan;35(1):123. doi: 10.1200/JCO.2016.69.9371. Epub 2016 Oct 31. J Clin Oncol. 2017. PMID: 28034066 No abstract available.
Comment on
-
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811535 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources